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Abstract
Background: Increased susceptibility of smokers to ambient PM may potentially promote development of COPD
and accelerate already present disease.
Objectives: To characterize the acute and subacute lung function response and inflammatory effects of controlled
chamber exposure to concentrated ambient fine particles (CAFP) with MMAD ≤ 2.5 microns in ex-smokers and
lifetime smokers.
Methods: Eleven subjects, aged 35–74 years, came to the laboratory 5 times; a training day and two exposure days
separated by at least 3 weeks, each with a post-exposure visit 22 h later. Double-blind and counterbalanced exposures
to “clean air” (mean 1.5 ± 0.6 μg/m3) or CAFP (mean 108.7 ± 24.8 μg/m3 ) lasted 2 h with subjects at rest.
Results: At 3 h post-exposure subjects’ DTPA clearance half-time significantly increased by 6.3 min per 100 μg/m3 of
CAFP relative to “clean air”. At 22 h post-exposure they showed significant reduction of 4.3% per 100 μg/m3 in FEV1
and a significant DLCO decrease by 11.1% per 100 μg/m3 of CAFP relative to “clean air”. At both 3 h and 22 h the HDL
cholesterol level significantly decreased by 4.5% and 4.1%, respectively. Other blood chemistries and markers of lung
injury, inflammation and procoagulant activity were within the normal range of values at any condition.
Conclusions: The results suggest that an acute 2 h resting exposure of smokers and ex-smokers to fine ambient
particulate matter may transiently affect pulmonary function (spirometry and DLCO) and increase DTPA clearance
half-time. Except for a post exposure decrease in HDL no other markers of pulmonary inflammation, prothrombotic
activity and lung injury were significantly affected under the conditions of exposure.
Keywords: CAFP, Chamber exposure, Spirometry, Older smokers, Ex-smokers, DTPA clearance half-time, Lung diffusing
capacity, Blood chemistry
Background
Numerous field and epidemiological studies have shown
associations between ambient particulate air pollution
exposure and longitudinal changes in peak expiratory
flow rates, respiratory symptoms, medication use, mortality
and morbidity, including hospital admissions for car-
diopulmonary disease [1]. Cigarette smoking can impair
lung function and, therefore, smokers and ex-smokers
may be more vulnerable to PM exposure [2]. Despite the
concentrated effort by the American Lung Association,
the American Heart Association and other agencies to
reduce smoking by the US population recent trend
estimates show that 1 in 5 adults still smoke. The
prevalence rate of current smokers in some states is as
high as 28% [3].
Because smoking is a leading cause of COPD, increased
susceptibility of smokers to ambient PM may potentially
promote development of COPD. The risk estimate for
residents of high pollution areas of developing COPD
was higher in past smokers than never smokers [4].
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Middle-aged current smokers exposed to ambient PM
showed a small but statistically significant negative
association between pulmonary function (FEV1) and
PM10 levels [5]. To date, very little is known about
whether smokers are more susceptible to PM since only
a few epidemiologic studies and no laboratory studies
have explored the effects of ambient PM on smokers.
Laboratory inhalation study of lung deposition of fine
particles has shown an increased deposition in smokers
which may potentially result in greater susceptibility to
injury by ambient PM [6]. Controlled exposure studies
and acute panel studies of nonsmokers have, except for
a few reporting a post-exposure decrease in DLCO [7],
generally failed to find any consistent lung function
changes associated with exposure to PM [8,9].
The general objective of the study was to examine
and characterize the acute and subacute lung function
response and inflammatory effects of controlled exposure
of middle-aged and older ex-smokers and lifetime smokers
to concentrated ambient fine particles (CAFP). More
specific objectives were to determine whether smokers
following controlled exposure to CAFP develop (a) decre-
ments in spirometry or DLCO, (b) increased respiratory
epithelial permeability as measured by 99mTc-DTPA
clearance, and (c) changes in pro-coagulant factors
and markers of inflammation, oxidative stress and lung
injury in peripheral venous blood.
Results
Subjects
Table 1 shows the physical characteristics, smoking history
expressed as packs per day per year (pack-years) and
baseline pulmonary function of the study participants.
All but two subjects (#1 and 2) who quit smoking 7
and 10 years ago, respectively, were current smokers.
Particle concentration
On one of the days each subject was exposed to clean
filtered air (CA) with particle concentration ranging from
0.0–5.8 μg/m3 (mean 1.5 ± 0.6). Any gaseous pollutants
were diluted by a factor of four. On the other day each
subject was exposed to CAFP concentration ranging
from 28.6 – 305.9 μg/m3 (mean 108.7 ± 24.8). Most of the
particles came from traffic in the vicinity of the facility.
Pulmonary function
Immediately following exposure estimated difference
in FVC and FEV1 response (Figure 1) between CA and
CAFP was −3.0 and −1.1% points per 100 μg/m3 of
CAFP, respectively. Three hours post-exposure this dif-
ference was −3.1 and −1.8% points, respectively. None
of these changes were statistically significant. However,
the difference between CA and CAFP at 22 h showed a
reduction of 4.4% (p = 0.101) and 4.3% points (p = 0.017)
per 100 μg/m3 for FVC and FEV1, respectively. None
of the subjects had to use bronchodilator at any time
during the study sessions or reported an increased use
of bronchodilator between exposure sessions. We found
no consistent changes in FEV1/FVC either following
CA (range 70.2%-72.1%) or CAFP (range 70.9%-72.7%)
exposures.
The RAW at 3 h and 22 h following CA exposure
showed 1.7% and −0.4% change from baseline; after
CAFP the respective changes were −0.7% and 6.0%, with
none of the changes being statistically significant.
Table 1 Physical characteristics and baseline pulmonary function
Subj Gender Race Age Height Weight Smoking BMI BSA FEV1 FEV1 FEV1/FVC DLCO**
# [yrs] [cm] [kg] [pk-yr] [m2] L/s [% pred] [%]
1 M* C 74 172 65.3 9.0 22.1 1.77 2.2 80.2 52.8 9.7
2 F* C 63 157 60.0 40.0 24.3 1.60 1.3 61.3 58.5 16.3
3 F C 39 157 114.6 48.0 46.5 2.10 1.6 60.9 57.0 20.3
4 M C 50 172 77.3 31.0 26.1 1.90 3.5 103.2 78.4 25.3
5 M B 42 183 75.8 39.0 22.6 1.97 3.3 92.9 72.0 35.5
6 F B 40 159 87.1 38.0 34.4 1.89 1.9 84.1 82.9 30.0
7 F C 46 163 61.3 30.0 23.1 1.66 2.9 109.8 81.7 17.1
8 F B 55 160 60.6 54.0 23.7 1.63 2.3 114.1 75.0 13.7
9 F C 35 168 82.1 39.0 29.1 1.92 3.7 123.0 71.5 22.6
10 F B 53 154 55.8 60.0 23.5 1.53 1.6 83.6 82.2 8.7
11 F B 35 165 82.7 12.0 30.4 1.90 2.4 96.5 78.2 15.1
Mean 48 165 74.8 27.8 36.4 1.80 2.5 91.8 72.3 20.0
SEM 4 3 5.2 2.2 4.7 0.10 0.2 6.1 3.5 2.6
*ex-smoker; **DLCO in ml/min/mm Hg;
M =male, F = female; C = Caucasian, B = black; BSA = body surface area; BMI = body mass index.
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Single breath DLCO decreased significantly by 11.1%
per 100 μg/m3 (p = 0.035 one sided) at 22 h following
exposure to CAFP (Figure 2).
99mTc-DTPA clearance
Following CA exposure mean 99mTc-DTPA clearance
half-time remained stable at 3 h and 22 h post-exposure
at 42.6 and 44.4 min, respectively (Figure 3). Exposure
to CAFP prolonged the clearance half-time at both 3 h
and 22 h to estimated means of 48.9 and 46.0 min at
100 μg/m3, respectively. The prolongation of clearance
half-time at 3 h by 6.3 min per 100 μg/m3 as compared
to CA was statistically significant (p < 0.026). We found
no significant changes in the C/P 99mTc-DTPA deposition
ratios at either post-CAFP exposure time.
NO concentration
Nasal and exhaled NO concentration changes were
small, inconsistent and not statistically significant at
any measurement period.
Peripheral venous blood tests
The changes in CBC with differential WBC are tabulated
in Table 2. The absolute neutrophil count at 22 h post
CAFP exposure was statistically significantly lower
than at 3 h after CAFP exposure but not different
from baseline. Neither the absolute nor percentage
differential WBC count for any other type of cell was
significantly different between sessions. The blood
chemistry panel variables were within normal range of
values at any exposure condition and sessions.
As shown in Figure 4, markers of lung injury, inflam-
mation and procoagulant activity were not significantly
affected by either the CA or CAFP exposures. However,
as shown in Figure 5, HDL cholesterol was significantly
reduced following CAFP relative to CA at 3 h (−4.5% per
100 μg/m3, p = 0.040) and 22 h (−4.1% per 100 μg/m3,
p = 0.011) post CAFP exposure. No other lipid panel
variables showed significant changes.
Discussion
Numerous epidemiologic studies have reported various
cardiopulmonary effects including increased acute mor-
bidity and mortality due to ambient exposure of elderly
Figure 1 Estimated differences between CAFP and CA
exposures for spirometric endpoints (FVC and FEV1) measured
immediately after and, at 3 h and 22 h after a two-hour expos-
ure. The estimates are expressed as % point differences per 100 μg/
m3 increase in PM concentration relative to the pre-exposure level.
Horizontal bars correspond to 95% confidence interval around the
mean value. The asterisk indicates significant difference between CA
and CAFP exposure (p = 0.008).
Figure 2 Barplot of DLCO changes as % point difference from
baseline measured at 3 h and 22 h post-exposure. Black bars
show estimated mean ± SEM at 0 μg/m3 of CA exposure and striped
bars at 100 μg/m3 of CAFP exposure. Asterisk indicates significant
difference between CA and CAFP exposures (11.1% decrease per
100 μg/m3, p = 0.035).
Figure 3 Bar plot of pulmonary 99mTc-DTPA clearance half-time
in measured units at 3 h and 22 h post-exposure. Black bars
show estimated mean ± SEM at 0 μg/m3 of CA exposure and striped
bars at 100 μg/m3 of CAFP exposure. Asterisk indicates significant
difference between CA and CAFP exposures (6.3% increase per
100 μg/m3, p = 0.026).
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individuals with COPD to fine ambient air PM [2,10,11].
Smokers at already increased risk of death from cardio-
pulmonary disease are even more health compromised
when repeatedly exposed to PM [12]. The authors
found the strongest respiratory morbidity association
with ambient PM2.5 to have zero or one day lag. Al-
though smoking is one of the prominent risk factors for
development of COPD that can be aggravated due to exposure to air pollution [13], very few studies have
explored the effects of fine PM and smoking under
controlled laboratory conditions. We report a small
though not statistically significant decrease in FVC and
FEV1 in elderly smokers and subjects with mild COPD
immediately after a 2 h CAFP and CA exposure at rest.
Post CAFP exposure the decrements persisted and the
FEV1 decrement became statistically significant at 22 h.
The reanalysis of data after removing two ex-smokers
still showed the decrease in FEV1 to be statistically
significant the day after exposure (22 h). In a study with a
similar protocol, both healthy and COPD elderly subjects
exposed to CAFP during light intermittent exercise
showed no statistically significant spirometric effects
although the healthy individuals had a small statistically
significant decrease in SpO2 immediately post-exposure
suggesting a transient gas exchange impairment [14].
However, in a subsequent study from the same laboratory
under similar conditions of exposure, healthy elderly
not only showed a statistically significant decrease in
SpO2 as in the previous study but a statistically significant
decrement in FEF25-75 22 h post-CAFP as well [15]. Thus,
the finding of a significant decrease in FEV1 at 22 post-
CAFP in our younger healthy smokers and ex-smokers
is in general agreement with the observation of Gong
et al. [15] reflecting mild impairment of large airways
in young subjects and of both large and small airways
in older individuals.
Table 2 Peripheral venous blood absolute cell count
(mean ± SEM )
Pre 3 h post 22 h post
RBC (×106/μL) Clean Air 4.30 ± 0.09 4.41 ± 0.11 4.39 ± 0.15
CAFP 4.49 ± 0.12 4.52 ± 0.14 4.41 ± 0.13
WBC (×103/μL) Clean Air 5.29 ± 0.46 5.89 ± 0.45 5.20 ± 0.34
CAFP 5.42 ± 0.37 6.24 ± 0.45 4.94 ± 0.23
Neutrophils (×103/μL) Clean Air 2.99 ± 0.30 3.18 ± 0.28 2.87 ± 0.20
CAFP 3.04 ± 0.22 3.56 ± 0.35 2.67 ± 0.22*
Lymphocytes (×103/μL) Clean Air 1.74 ± 0.28 2.07 ± 0.25 1.76 ± 0.29
CAFP 1.81 ± 0.31 2.06 ± 0.26 1.71 ± 0.28
Monocytes (×103/μL) Clean Air 0.40 ± 0.01 0.45 ± 0.03 0.38 ± 0.02
CAFP 0.39 ± 0.03 0.45 ± 0.02 0.39 ± 0.02
Platelets (×103/μL) Clean Air 231 ± 16 241 ± 17 232 ± 13
CAFP 258 ± 21 267 ± 23 241 ± 18
*p = 0.0326 (3 h vs. 22 h)
Figure 4 Estimated differences between CAFP and CA
exposures for selected venous blood markers of inflammation,
prothrombotic activity, and lung injury measured at 3 h and
22 h post exposure. The estimates are expressed as % point
differences per 100 μg/m3 increase in PM concentration and relative
to pre-exposure level. Horizontal bars correspond to 95% confidence
intervals. None of the mediators showed a statistically significant
change. For abbreviations see text.
Figure 5 Estimated differences between CAFP and CA
exposures for selected venous blood lipids measured at 3 h
and 22 h post-exposure. The estimates are expressed as % point
differences per 100 μg/m3 increase in PM concentration relative to
pre-exposure level. Horizontal bars correspond to 95% confidence in-
tervals. Only HDL cholesterol decreased significantly at both time
points (p = 0.040 and 0.011, respectively). For abbreviations see text.
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In healthy individuals PM2.5 deposits predominantly in
the peripheral airways [16]. However, bronchoconstriction
of conducting airways will enhance central deposition of
fine particles [6]. The epidemiologic study of the Austrian
Project on Health Effects of Particulate Matter (AUPHEP)
with the population ranging from pre-school children
to the elderly has shown that increases in RAW were
most consistently associated with PM2.5 [17]. In our
study we observed an insignificant increase in RAW at
22 h post CAFP. Generally, the lung deposition of fine
PM is higher in smokers (and even more so in COPD
subjects) when compared to healthy individuals. The
enhanced deposition was proportional to the severity of
obstruction. In both smokers and COPD subjects the
deposition fraction was negatively associated with FEV1
(% predicted) as well as positively associated with SRAW
[6]. A computer simulation model showed that in COPD
the overall deposition of fine PM is further increased
and shifted to proximal airways as compared to healthy.
Such a shift most likely increased PM dose per unit of
proximal airways surface area [18]. Most likely such
redistribution is due to an increased production of
mucus combined with airways narrowing of smokers and
individuals with COPD. We did not measure fractional
lung deposition of fine PM in the present study but our
pulmonary function observations are consistent with
the above studies. We speculate that the decline in
FEV1 at 22 h following CAFP exposure may be due to
an enhanced deposition of fine PM in large airways, and
the delay of the effect is consistent with the observation
of Pope et al. [12] that the maximal respiratory effects
lagged a day following exposure to fine PM.
A substantial component of PM2.5 is ultrafine particles
(UFP) of 0.1 μm or less. These UFP are preferentially
deposited in small airways. A very recent study in healthy
subjects has shown that the primary UFP deposition
site is the alveolar region. The deposited particles
cleared very slowly with no significant elimination over
several days [19]. UFP deposition (as a component of
fine PM exposure) was reported to be higher in smokers
when compared to healthy individuals [6]. In healthy
subjects controlled exposure to 50 μg/m3 elemental carbon
UFP resulted in a small transient increase in RAW, and
statistically significant decrease in FEF25-75 and DLCO
at 21 h post-exposure [7]. The response of our subjects
to CAFP was very similar: a small increase in RAW, a
decrease in FEV1 and DLCO at 3 h followed by even
greater, statistically significant, decrease in the latter
two endpoints at 22 h post exposure. Although the
effects UFP may potentially have on alveolar epithelium
are yet unclear it is plausible that the gas exchange
function of the alveolar region may be compromised.
Pietropaoli and colleagues [7] speculated that the UFP
effects observed in their study of healthy individuals
are due to bronchoconstriction and pulmonary vaso-
constriction. Such transient effects are unlikely to have
any major health consequences in healthy individuals.
However, in smokers who have already reduced spirometric
function and DLCO [20] additional reduction in spirometric
function and DLCO may further aggravate and even limit
subjects’ cardiopulmonary function and physical activity.
Although it is unclear what mechanisms may have
been involved in DLCO reduction due to PM inhalation,
a transient significant increase in DTPA clearance half-time
(T½)(i.e., decrease in clearance rate) at 3 h post-exposure
as compared to CA suggests either decreased pulmonary
epithelial permeability or increased thickness of the
alveolar-capillary barrier. Few studies have explored
the effects of fine PM exposure on DTPA clearance.
Inhalation of fine iron oxide particles (12.7 mg/m3)
for 30 min at rest by healthy young volunteers had
no significant effects on DLCO and DTPA clearance
half-time either at 0.5 or 24 h post inhalation [21].
Prolonged 24 h chamber exposure of young healthy
exercising individuals to predominantly coarse ambient
PM failed to have any significant effects on the blood-
gas barrier as measured by DTPA clearance rate [22].
Other studies, however, have shown increased epithelial
permeability as assessed by DTPA clearance rate in
smokers vs. nonsmokers [23,24]. Interpretation of these
and of our findings is complicated by likely differences
in pre-existing chronic inflammation and changes in
airway function and morphology associated with chronic
smoking. Evidence for chronic inflammation in our
subjects is supported by baseline their DTPA clearance
half-time being more than twice as rapid as what we
observed previously in healthy non-smoking subjects
[21] (mean halftime of 43 vs. 105 min in non-smokers).
We speculate that, in our study, fine PM depositing
into likely inflamed airways and UFP depositing primarily
in the alveolar region induced a transient interstitial
edema, effectively thickening the blood-gas barrier which
resulted in reduced DLCO and an increased DTPA clear-
ance half-time. This interpretation is supported by the
work of Foster et al. [25] which showed that mild air-
way wall edema due to inflamed airways in sheep
reduced the rate of DTPA clearance rate.
The significant respiratory response contrasts with min-
imal effects on a large number of measured peripheral
blood endpoints (coagulation factors, inflammatory medi-
ators, and blood cell count, blood chemistries and lipids).
With the exception of changes in HDL we did not find
any meaningful associations between the changes in
blood variables, PM concentration or pulmonary function
changes. Considering a relatively short exposure time at
rest it is unlikely that the concentration of the particles
was high enough to induce systemic effects. A similar
study with a higher level of CAFP and inclusion of light
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exercise also reported a lack of significant changes in
CBC, differential WBC and procoagulation factors [14].
On the other hand, Ghio et al. [8] reported neutrophilia in
younger individuals exposed to Chapel Hill CAFP for 2 h
while alternating 15 min exercise (minute ventilation of
about 50 L/min) with 15 min rest to a slightly higher
PM2.5 concentration (120.5 ± 14 μg/m
3) than in our study.
In our middle-aged cohort we observed only a small
increase in absolute WBC at 3 h post exposure to both
CA and CAFP. The absence of consistent inflammatory,
coagulation and blood cell count changes suggest that
the respective mechanisms were not sufficiently activated
by relatively low fine PM exposure load in our study.
Even in studies of elderly where the average fine PM
concentration was twice as high as ours the induced
changes in the above endpoints were minimal if any
[14,15]. In our cohort of 11 smokers we did not observe
any enhanced pulmonary or inflammatory response in
those individuals either. Very recently, however, Rice
et al. [26] reported a significant decrease in circulating
HDL cholesterol level but no other lipids in welders
acutely exposed to primarily PM2.5 welding fumes. Our
results parallel these findings, also showing a significant
post-exposure decrease in HDL at 3 and 22 h without
any significant changes in other lipids.
Conclusions
We found that in 11 middle-aged to elderly mostly
female smokers, including two ex-smokers, there were
statistically significant lung function decrements after
a 2 h exposure to concentrated fine Chapel Hill PM
(CAFP) at rest. With respect to our a priori primary
endpoint measures we found a significant reduction in
FEV1 at 22 h post-exposure and a significant increase
in DTPA clearance half-time at 3 h post-exposure. The
coherence of these observations contrasts with randomness
of response in various exploratory endpoints – serum
chemistries and protein panels, and procoagulants. These
changes were not driven by two ex-smokers since the
removal of their data did not change the statistical
significance of these primary outcomes. These findings
are consistent with mild airways inflammation and
plausibly with transient interstitial edema. The findings
in other exploratory endpoints such as hematologic,
serum chemistry and protein panels, and procoagulants
appeared to be random. The lack of consistent inflammatory
response makes it difficult to assess the systemic significance
of the observed effects. Since these effects developed
after resting inhalation of relatively low concentrations
of CAFP the lung function changes might be expected
to be more pronounced in individuals with pre-existing
conditions, with higher inhaled CAFP concentrations
and with increased ventilation attendant to exercise.
Methods
Subjects
Seventeen current and ex-smokers, aged 35–74 yrs,
recruited from the general population who initially
qualified for the study approved by the UNC IRB and the
EPA but for various technical reasons only 11 participated
in the exposure phase of the study. On the day of exposure
and until the completion of the study and discharge the
next day subjects were not allowed to smoke but were
allowed to use their own nicotine gum/patch.
Protocol
Eligible volunteers came to the laboratory 5 times; a
training day and two exposure days with 22 h follow-up
separated by at least 3 weeks. Double-blind and counter-
balanced exposures to CA or CAFP with an MMAD of
less than 2.5 microns lasted 2 h with subjects resting
during the exposure. During the training session the
subjects were familiarized with and performed most of
the study procedures. As part of this session ECG leads
for 24 h Holter monitoring were placed on the subjects
(Mortara, Milwaukee, WI). Subjects were excluded from
further study if the Holter reviewed by a cardiologist
showed significant arrhythmia or evidence of ischemia.
Upon arrival in the laboratory on the exposure day,
medical personnel ascertained the subject’s general health,
took vital signs and evaluated respiratory symptoms.
Subsequently, the subjects performed pre-exposure lung
function tests, had ECG electrodes attached for safety
monitoring, had blood samples drawn and entered the
exposure chamber with conditions blinded to both the
subject and the investigator. ECG and finger pulse
SpO2 were monitored continuously during the exposure
and spirometric measures of lung function were checked
midway through the exposures. Subjects were asked to
refrain but were not prohibited from using inhaled
bronchodilators during exposures; if medication use was
necessary subjects were instructed to maintain consistent
medication use across the two exposures. After completing
post-exposure testing and blood draw the subjects were
discharged. The next morning subjects returned to the
facility for 22 h post exposure testing.
Exposure chamber and PM generation
All exposures were carried out at the EPA Human Studies
Facility (HSF) on the University of North Carolina campus
at Chapel Hill, NC. A fine particle concentrator [27]
installed at the EPA HSF and described earlier [28] was
used for this study.
Procedures
Spirometry was measured before, immediately, 3 h and
22 h after exposure using Sensormedics Vmax 229 system
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(Yorba Linda, CA) conforming to recommended ATS/
ERS procedure [29].
The permeability of the respiratory epithelium was
assessed at 3 h and 22 h post exposure by monitoring
the pulmonary clearance of an inhaled radiolabeled
tracer molecule (99mTc-DTPA) from the lungs into the
blood using a gamma camera. The rate of clearance of
radioactivity from the thorax serves as an index of alveolar
epithelial permeability and the results are reported as
the calculated clearance half-time (T1/2) [21]. Regional
deposition within the central (C) and peripheral (P) regions
of the lung was examined by calculating a central to
peripheral (C/P) ratio based on counts from the initial
one minute dynamic image following deposition of the
inhaled radiolabeled DTPA aerosol [30].
As secondary endpoints, we measured DLCO [31] and
plethysmographic airway resistance using Sensormedics
Vmax system, and exhaled (bag collection) and nasal
(on-line) nitric oxide [32] using Sievers 270B analyzer
(GE Analytical, Boulder, CO).
Blood was drawn immediately prior to and both 3 h
and 22 h after exposure to obtain peripheral venous blood
cell counts and blood chemistry measurements including
a complete blood count (CBC), circulating levels of
inflammatory cytokines, serum electrolytes, lipoproteins
(triglycerids, total cholesterol, HDL, LDL) and indicators
of kidney (creatinine, BUN, BUN/creatinine ratio) and
liver (bilirubin, total protein, albumin, globulin, ALP,
AST-SGOT, ALT-SGPT, GGT) function. Plasma assays
included tPA, PAI-1, vWF, CRP, quantitative CRP, Clara
cell 16 protein (CCP), and D-dimer.
Statistical approach
The primary variables of interest selected a priori were
FEV1 and
99mTc-DTPA clearance. The other reported
endpoints were of secondary interest. All endpoints with
the exception of 99mTc-DTPA clearance were acquired at
baseline (pre-exposure), 3 h and 22 h post-exposure.
Spirometry was also measured immediately post-exposure
while DTPA clearance was only measured at 3 h and 22 h
post-exposure. The endpoints with baseline values were
expressed as % of baseline (100*post/pre) to control
for day-to-day variability. The differences in responses
between CA and CAFP were examined using linear mixed
effects models with subject-specific random intercepts
to account for repeated measures and subject CAFP
exposure level variability. The differences in responses
between CA and CAFP were considered separately
for each time point (immediately post, 3 h and 22 h
post-exposure). They were expressed per 100 μg/m3 of PM
relative to baseline in normalized endpoints (spirometry,
DLCO and blood data) and in measured units for
99mTc-
DTPA clearance half-time. R statistical software (Version
2.11.1) was used for the analysis and to generate plots. To
determine statistical significance at α = 0.05 two-tailed
test was used to evaluate all data except DLCO where
one-tailed test was used.
In this study a large number of endpoints were measured
and so a question of multiple comparisons correction is
of concern. For the primary endpoints (FEV1, DTPA)
multiple comparison adjustment is not appropriate since
they were declared as such a priori and are not covariates.
While the study was powered on FEV1 changes observed
in other studies we measured a number of secondary
endpoints not studied under these conditions in this pop-
ulation. Among approximately 40 blood exploratory end-
points, only one (HDL) was found to have a p-value <0.05.
The other one was DLCO. The seemingly significant
change of these two endpoints might be due to chance
rather than due to CAFP exposure. After adjusting for
multiple testing, the HDL and DLCO changes would
not have been statistically significant. However, the
small sample size may have an impact on the rate of
false negative findings particularly when CAFP-induced
changes may be small.
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